INSOMNIA TREATMENT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026 - 2033)

Insomnia, or sleeplessness, is a sleep disorder in which people have trouble sleeping. Signs and symptoms may include difficulty falling or staying asleep and not feeling well-rested. Sleeping pills may also be used, but should be monitored for side effects. Sometimes prescription drugs used to treat depression may ease insomnia when taken in lower doses. Cognitive behavioral therapy for insomnia, CBT-I, is usually recommended as the first line of treatment. CBT-I is a structured program that helps people identify and replace thoughts and behaviors that cause or worsen sleep problems with habits that promote sound sleep.

Market Dynamics

High prevalence of sleep disorders, growing demand for safe and effective treatment, increase in awareness among people, and rapidly growing geriatric population worldwide is expected to augment the growth of the global insomnia treatment market during the forecast period. The prevalence of insomnia is higher in elderly than in the younger population. Physiologic changes of aging, chronic medical illnesses, and environmental conditions contribute to insomnia in the elderly. Thus, with the growing geriatric population, the demand for safe & effective insomnia treatment worldwide. For instance, according to the World Health Organization (WHO), one in six people in the world will be aged 60 years or over by 2030, and the world’s population of people aged 60 years and older will double (2.1 billion) by 2050.

Key features of the study

• This report provides in-depth analysis of the global insomnia treatment market, and provides market size (USD Bn) and compound annual growth rate (CAGR %) for the forecast period (2026–2033), considering 2025 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global insomnia treatment market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Innovative Neurological Devices, Cerêve Inc., Sanofi SA, Pfizer Inc., Paratek Pharmaceuticals Inc., Merck & Co. Inc., Takeda Pharmaceutical Company Ltd., Ebb Therapeutics, and Electromedical Products International Inc., among others.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global insomnia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global insomnia treatment market.

Market Segmentation

• Treatment Type Insights (Revenue, USD Bn, 2026 - 2033)
• Drug
• Device
• Distribution Channel Insights (Revenue, USD Bn, 2026 - 2033)
• Hospital Pharmacies
• Retail Pharmacies
• Other Distribution Channels
• Regional Insights (Revenue, USD Bn, 2026 - 2033)
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC
• Israel
• Rest of Middle East
• Africa
• North Africa
• Central Africa
• South Africa
• Key Players Insights
• Innovative Neurological Devices
• Cerêve Inc.
• Sanofi SA
• Pfizer Inc.
• Paratek Pharmaceuticals Inc.
• Merck & Co. Inc.
• Takeda Pharmaceutical Company Ltd.
• Ebb Therapeutics
• Electromedical Products International Inc.